Investor Relations

Company Overview

Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in this indication presents the highest chance of success with the greatest commercial opportunity.

Market One Interview

Latest Presentation

Upcoming Events

April 30 – May 1, 2019

Bloom Burton & Co. Healthcare Investor Conference 2019

Toronto
April 30, 2019

2019 Bloom Burton & Co. Investor Conference

Metro Toronto Convention Centre, Toronto, ON
May 2, 2019

Annual General Meeting

Toronto
View All Events

Stock Information

Symbol

Nasdaq ONCY

Price

Change

Symbol

TSX ONC

Price

Change

Investor Relations

Michael Moore
Vice President Investor Relations and Corporate Communications
T: (403) 670-7377 Ext. 2
mmoore@oncolytics.ca